Both proteasomes and lysosomes degrade the activated erythropoietin receptor.

Activation of the erythropoietin receptor (EpoR) after Epo binding is very transient because of the rapid activation of strong down-regulation mechanisms that quickly decrease Epo sensitivity of the cells. Among these down-regulation mechanisms, receptor internalization and degradation are probably the most efficient. Here, we show that the Epo receptor was rapidly ubiquitinated after ligand stimulation and that the C-terminal part of the Epo receptor was degraded by the proteasomes. Both ubiquitination and receptor degradation by the proteasomes occurred at the cell surface and required Janus kinase 2 (Jak2) activation. Moreover, Epo-EpoR complexes were rapidly internalized and targeted to the lysosomes for degradation. Neither Jak2 nor proteasome activities were required for internalization. In contrast, Jak2 activation was necessary for lysosome targeting of the Epo-EpoR complexes. Blocking Jak2 with the tyrphostin AG490 led to some recycling of internalized Epo-Epo receptor complexes to the cell surface. Thus, activated Epo receptors appear to be quickly degraded after ubiquitination by 2 proteolytic systems that proceed successively: the proteasomes remove part of the intracellular domain at the cell surface, and the lysosomes degrade the remaining part of the receptor-hormone complex. The efficiency of these processes probably explains the short duration of intracellular signaling activated by Epo.

[1]  V. Broudy,et al.  Internalization of the thrombopoietin receptor is regulated by 2 cytoplasmic motifs. , 2003, Blood.

[2]  M. Ciesielski,et al.  Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function , 2000, Oncogene.

[3]  P. Mayeux,et al.  The erythropoietin receptor of rat erythroid progenitor lens. Characterization and affinity cross-linkage. , 1987, The Journal of biological chemistry.

[4]  Yosef Yarden,et al.  Endocytosis of Receptor Tyrosine Kinases Is Driven by Monoubiquitylation, Not Polyubiquitylation* , 2003, Journal of Biological Chemistry.

[5]  T. Malek,et al.  The Proteasome Regulates Receptor-mediated Endocytosis of Interleukin-2* , 2001, The Journal of Biological Chemistry.

[6]  Rey-Huei Chen,et al.  Molecular interpretation of ERK signal duration by immediate early gene products , 2002, Nature Cell Biology.

[7]  F. Verdier,et al.  Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. , 2000, The Journal of biological chemistry.

[8]  D. Nimbalkar,et al.  Erythropoietin Receptors Associate with a Ubiquitin Ligase, p33RUL, and Require Its Activity for Erythropoietin-induced Proliferation* , 2003, Journal of Biological Chemistry.

[9]  A. Levitzki,et al.  Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor , 1996, Nature.

[10]  S. Fuchs,et al.  SCFHOS ubiquitin ligase mediates the ligand‐induced down‐regulation of the interferon‐α receptor , 2003 .

[11]  A. Dautry‐Varsat,et al.  Involvement of the ubiquitin/proteasome system in sorting of the interleukin 2 receptor beta chain to late endocytic compartments. , 2001, Molecular biology of the cell.

[12]  P. van Kerkhof,et al.  The ubiquitin-proteasome pathway regulates lysosomal degradation of the growth hormone receptor and its ligand. , 2001, Biochemical Society transactions.

[13]  N. Copeland,et al.  A novel cytokine‐inducible gene CIS encodes an SH2‐containing protein that binds to tyrosine‐phosphorylated interleukin 3 and erythropoietin receptors. , 1995, The EMBO journal.

[14]  H. Beug,et al.  FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1 , 2004, The Journal of cell biology.

[15]  L. Platanias,et al.  Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1 , 1996, Molecular and cellular biology.

[16]  Stefan N. Constantinescu,et al.  The Erythropoietin Receptor: Structure, Activation and Intracellular Signal Transduction , 1999, Trends in Endocrinology & Metabolism.

[17]  A. Dautry‐Varsat,et al.  Down-regulation of high affinity interleukin 2 receptors in a human tumor T cell line. Interleukin 2 increases the rate of surface receptor decay. , 1988, The Journal of biological chemistry.

[18]  H. Nakauchi,et al.  Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival. , 1991, Cancer research.

[19]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[20]  M. Martinez-Moczygemba,et al.  Proteasomal regulation of betac signaling reveals a novel mechanism for cytokine receptor heterotypic desensitization. , 2001, The Journal of clinical investigation.

[21]  B. Deurs,et al.  Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. , 1999, Molecular biology of the cell.

[22]  N. Casadevall,et al.  Solubilization and hydrodynamic characteristics of the erythropoietin receptor. Evidence for a multimeric complex. , 1990, European journal of biochemistry.

[23]  G. Strous,et al.  Dimerization, ubiquitylation and endocytosis go together in growth hormone receptor function , 2002, FEBS letters.

[24]  S. Ruscetti,et al.  Involvement of the Ubiquitin-Proteasome Pathway in the Degradation of Nontyrosine Kinase-Type Cytokine Receptors of IL-9, IL-2, and Erythropoietin1 , 2000, The Journal of Immunology.

[25]  H. Lodish,et al.  The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. , 2001, Molecular cell.

[26]  A. Barrett,et al.  CA074 methyl ester: a proinhibitor for intracellular cathepsin B. , 1992, Archives of biochemistry and biophysics.

[27]  Y. Yarden,et al.  The role of ubiquitylation in signaling by growth factors: implications to cancer. , 2003, Seminars in cancer biology.

[28]  K Kobylarz,et al.  Acute cholesterol depletion inhibits clathrin-coated pit budding. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. van Kerkhof,et al.  Endocytosis and Degradation of the Growth Hormone Receptor Are Proteasome-dependent* , 2000, The Journal of Biological Chemistry.

[30]  N. Casadevall,et al.  Erythropoietin induces the tyrosine phosphorylation of its own receptor in human erythropoietin-responsive cells. , 1992, The Journal of biological chemistry.

[31]  I. Dusanter-Fourt,et al.  Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway , 1997, Molecular and cellular biology.

[32]  A. Yoshimura,et al.  CIS3/SOCS-3 Suppresses Erythropoietin (EPO) Signaling by Binding the EPO Receptor and JAK2* , 2000, The Journal of Biological Chemistry.

[33]  V. Broudy,et al.  Erythropoietin receptor characteristics on primary human erythroid cells. , 1991, Blood.

[34]  T. ten Broeke,et al.  Growth Hormone Receptor Ubiquitination, Endocytosis, and Degradation Are Independent of Signal Transduction via Janus Kinase 2* , 2001, The Journal of Biological Chemistry.

[35]  G. Strous,et al.  The ubiquitin–proteasome pathway and the regulation of growth hormone receptor availability , 2002, Molecular and Cellular Endocrinology.

[36]  W. Cavenee,et al.  Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Patrick Mayeux,et al.  Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. , 2002, The New England journal of medicine.

[38]  P. Mayeux,et al.  Erythropoietin (Epo) receptor and Epo mimetics. , 1999, Advances in nephrology from the Necker Hospital.

[39]  D. Reijngoud,et al.  Relationship between medium pH and that of the lysosomal matrix as studied by two independent methods. , 1976, Biochimica et biophysica acta.

[40]  Olivier Hermine,et al.  Caspase Activation Is Required for Terminal Erythroid Differentiation , 2001, The Journal of experimental medicine.

[41]  D. Neumann,et al.  Intermediates in degradation of the erythropoietin receptor accumulate and are degraded in lysosomes. , 1993, The Journal of biological chemistry.

[42]  G. Longmore,et al.  Activation of the erythropoietin receptor is not required for internalization of bound erythropoietin. , 1999, Blood.

[43]  A. Dautry‐Varsat,et al.  Interleukin 2 receptors and detergent-resistant membrane domains define a clathrin-independent endocytic pathway. , 2001, Molecular cell.

[44]  B. Avalos,et al.  Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia. , 1999, Blood.

[45]  I. Touw,et al.  Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/acute myeloid leukemia. , 1999, Blood.

[46]  Ursula Klingmüller,et al.  Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals , 1995, Cell.

[47]  Zhixiang Wang,et al.  Internalization of Inactive EGF Receptor into Endosomes and the Subsequent Activation of Endosome-Associated EGF Receptors , 2002, Science's STKE.

[48]  C. Lacombe,et al.  Erythropoietin Induces the Tyrosine Phosphorylation of Insulin Receptor Substrate-2 , 1997, The Journal of Biological Chemistry.

[49]  S. Fuchs,et al.  SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. , 2003, The EMBO journal.

[50]  H. Lodish,et al.  Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[51]  C. Lacombe,et al.  Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. , 2003, Blood.

[52]  A. Yoshimura,et al.  Proteasomes Regulate Erythropoietin Receptor and Signal Transducer and Activator of Transcription 5 (STAT5) Activation , 1998, The Journal of Biological Chemistry.

[53]  Z. Kam,et al.  c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. , 1998, Genes & development.

[54]  E Morelon,et al.  Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains , 1995, The Journal of cell biology.